Market closed·Syncing…
Market closed · Close · 18 Nov

Bharat Parenterals Limited BPLPHARMAshare price and chart

Bharat Parenterals closed at ₹2,440.00 on 18 November 2026, up 10.51% on the day. The range since listing is ₹1,125.70 to ₹2,492.80.

₹2,440.00The price one share last traded at, in rupees.+10.51% · ₹232.06
Low since listing ₹1,12696% up the rangeThe highest and lowest price the share has traded at in the past year, and where today's price sits between the two.high ₹2,493

Daily candlesEach candle is one trading day. The chart opens on the last year; drag back past the start or open full screen and the rest loads, back to listing (or the first day in our data). The body runs from the open to the close, the thin lines to the high and low. Green closed up, red closed down.

Loading prices…

Split and bonus adjusted daily candles. Drag back past the start, or open full screen, and its whole history loads. Scroll or pinch to zoom; full screen adds indicators, drawing and measuring.

Test a strategy on BPLPHARMA

Real prices, every charge counted. Pick one or write your own.

Technical snapshotHow the share has been behaving: its momentum, its trend, how much of the trading was real buying to keep, and its returns.

EOD 18 Nov
RSI (14) · 30 oversold, 70 overboughtA score from 0 to 100 showing how strong recent up days were against recent down days.
73.8Overbought
0 oversold3070overbought 100
Delivery · bought to hold vs churnOf all the shares traded in a day, the share that actually changed hands and went into someone's demat account, rather than being bought and sold the same day.
12.4%Below average - weaker conviction
today 12.4%20d avg 44.8%

The share of traded quantity that was actually delivered (not squared off intraday) - high delivery vs its 20-session average suggests real buying or holding, not just churn.

vs 50 DMAHow far today's close is above or below the average closing price of the last 50 trading days. It shows the medium-term trend.+35.1%1 monthHow much the share price has changed over the period.+41.1%3 monthsHow much the share price has changed over the period.+92.9%Vol 30dHow much the share has actually been moving day to day, stated as a yearly percentage. 30% means it swung roughly 30% a year at that pace.66.3%

Returns and valuationWhat the market pays for this company and how well the business uses its money.

Market capWhat the whole company is worth on the stock market: share price times the number of shares. It measures size, not quality.₹1,682 Cr18 NovDividend yieldThe cash paid out in a year as a percentage of today's share price. A 2% yield means ₹2 a year on a ₹100 share.0.04%last 12 months

Against its sectorWhere this company ranks among similar companies on each measure.

Pharmaceuticals · 141 peers · medians
Net marginOf every ₹100 of sales, how much is left as profit after all costs, interest and tax.-2.42%vs 10.23% median
Lowest: MEDIORG -86.72%Highest: SHUKRAPHAR 38.89%
Revenue growthHow much sales grew in the latest quarter against the same quarter a year earlier.110.9%vs 20.87% median
Lowest: NECLIFE -99.78%Highest: SHUKRAPHAR 652.15%

What the numbers sayShort plain statements about this company's latest figures.

Written by fixed rules

Latest quarterIn the quarter to September 2026 (results filed 29 Oct 2026), sales rose 110.9% from a year earlier to ₹136 cr and profit turned positive at ₹11.8 cr after a loss of ₹8.6 cr a year earlier.

Worth watching
  • Reported a loss in FY25 and FY26.
  • Profit before interest covered interest 1.7 times in FY26 (₹4 cr of interest).

Each line is written by a fixed rule from the company's own filings and share price, and names the figures it uses. It describes what happened; it is not advice about the share.

Dividend historyCash the company has paid per share, year by year.

₹40 / year
Paid 1 of 1 yrs
on ₹1 lakh at today's price · 0.04% yield · ₹1/share
What each year paid, on ₹1 lakh
41
26*
* 2026 so far - more may still be declared this year

2026 has paid ₹1.00 per share, about ₹41 on ₹1 lakh at today's price. Dividends are at the company's discretion and can be cut or skipped.

Backtest idea · BPLPHARMAMACD momentum

Momentum turning up, only while the long trend is up.

BuyMACD crosses above signal, price above 200-day SMA
SellMACD crosses back below
Real prices · every charge countedRun on BPLPHARMA
Backtest idea · BPLPHARMALower band bounce

Buys a stretch below the usual range, sells on the way back.

BuyCloses below the lower Bollinger band
SellBack at the middle band, or 15 days
Real prices · every charge countedRun on BPLPHARMA
Backtest idea · BPLPHARMASupertrend rider

Stays in while the trend line says up, out when it flips.

BuySupertrend turns up
SellSupertrend turns down
Real prices · every charge countedRun on BPLPHARMA
Your own ideaWrite a rule for BPLPHARMA in plain English“Buy BPLPHARMA when …”
Start writing
Buy the dip on BPLPHARMABuy when RSI(14) drops below 30
52-week high breakout on BPLPHARMABuy when closes at a 52-week high
Golden cross on BPLPHARMABuy when 50-day EMA crosses above 200-day
Stochastic oversold on BPLPHARMABuy when stochastic %K drops below 20
Pullback in an uptrend on BPLPHARMABuy when RSI(14) below 40, price above 200-day EMA

Key ratios at a glanceThe eight figures most people check first, each placed against companies in the same industry.

Against its sector
Market capWhat the whole company is worth on the stock market: share price times the number of shares. It measures size, not quality.
₹1,682 cr
Larger than 42% of 141 peers
sector middle ₹2,706 cr
Dividend yieldThe cash paid out in a year as a percentage of today's share price. A 2% yield means ₹2 a year on a ₹100 share.
0.0%
Around the middle of 141 peers
sector middle 0.1%
Sales growthHow much sales grew in the latest quarter against the same quarter a year earlier.
+110.9%
Higher than 94% of 130 peers
sector middle +20.9%

Peers are the listed companies in the exchange's own industry group: Pharmaceuticals. Balance-sheet figures are from the latest filed balance sheet; trends show each financial year we hold.

Revenue and profit, year by yearSales and net profit by financial year or by quarter.

Sales and net profit
FY25FY26
SalesNet profitfell vs last yearEach on its own scale · hover a bar for its figures
Op. marginOf every ₹100 of sales, the profit from the main business before depreciation, interest and tax.-5.4%FY26SalesMoney earned from selling the company's goods and services, before any costs. Also called revenue.₹345 CrFY26Net profitWhat is left for shareholders after all costs, interest and tax.₹-27 CrFY26

Where every ₹100 of sales goesHow each ₹100 the company sold was spent, and how much stayed as profit.

FY26

In FY26, of every ₹100 of sales it kept ₹0.0 as profit. Other income added ₹2.8.

Where it wentPer ₹100 of sales
Running costs₹105.4Depreciation₹2.5Interest₹1.1Tax₹1.8

How fast it has grownCompound growth a year in sales and profit, over 3 and 5 financial years, beside the latest quarter.

Compounded a year
3 years5 yearsLatest qtr
Sales--+110.9%
Profit---
3 and 5 years are compounded a year across full financial years. The latest quarter is against the same quarter a year earlier.

Health check, year by yearMargins, returns and debt for each financial year, so you can see the direction.

MeasureFY25FY26
Operating marginOf every ₹100 of sales, the profit from the main business before depreciation, interest and tax.0.8%-5.4%
Net marginOf every ₹100 of sales in the year, how much was left as profit after everything.-12.8%-7.9%
Interest coverHow many times the company's profit before interest could pay its interest bill.-1.0x1.7x

Each row against this company's own usual level: green better, red worse, grey close to it.

Backtest idea · BPLPHARMAStochastic oversold

Buys when the close sits near the bottom of its recent range.

BuyStochastic %K drops below 20
Sell8% profit, or after 15 days
Real prices · every charge countedRun on BPLPHARMA
Backtest idea · BPLPHARMAPullback in an uptrend

Buys a pause inside a rising trend.

BuyRSI(14) below 40, price above 200-day EMA
Sell8% profit, or after 30 days
Real prices · every charge countedRun on BPLPHARMA
Backtest idea · BPLPHARMABuy the dip

Buys after a sharp fall, betting on a bounce.

BuyRSI(14) drops below 30
Sell10% profit, or after 20 days
Real prices · every charge countedRun on BPLPHARMA
Backtest idea · BPLPHARMA52-week high breakout

Buys strength, when the price makes a new one-year high.

BuyCloses at a 52-week high
Sell8% stop loss
Real prices · every charge countedRun on BPLPHARMA
Backtest idea · BPLPHARMAGolden cross

Follows the long trend: in when the fast average crosses above the slow one.

Buy50-day EMA crosses above 200-day
SellWhen it crosses back below
Real prices · every charge countedRun on BPLPHARMA
MACD momentum on BPLPHARMABuy when MACD crosses above signal, price above 200-day SMA
Lower band bounce on BPLPHARMABuy when closes below the lower Bollinger band
Supertrend rider on BPLPHARMABuy when supertrend turns up
Buy the dip on BPLPHARMABuy when RSI(14) drops below 30
52-week high breakout on BPLPHARMABuy when closes at a 52-week high

Peers side by sideCompanies in the same exchange-defined industry group, largest first. Tap a heading to sort.

Pharmaceuticals
CompanyWhat the whole company is worth on the stock market: share price times the number of shares. It measures size, not quality.How many rupees investors pay today for one rupee of the company's yearly profit. A P/E of 20 means paying ₹20 for ₹1 of annual profit.The share price against the shareholders' money per share on the balance sheet. It asks what you pay for each rupee the owners have in the business.How much profit the company made on the shareholders' money in the business. 15% means ₹15 of profit a year on every ₹100 of owners' money.How much operating profit the company made on all the money in the business, whether it came from owners or lenders.Borrowings compared with the shareholders' money. 1 means the company owes as much as its owners have put in; 0 means no borrowings.Of every ₹100 of sales, how much is left as profit after all costs, interest and tax.How much sales grew in the latest quarter against the same quarter a year earlier.The cash paid out in a year as a percentage of today's share price. A 2% yield means ₹2 a year on a ₹100 share.
SUNPHARMA
Sun Pharmaceutical Industries Limited
4.49 L cr41.0x5.0x14.7%19.1%0.0317.8%+11.9%0.85%
DIVISLAB
Divi's Laboratories Limited
2.93 L cr87.2x16.3x16.2%21.5%0.0027.6%+35.4%0.27%
TORNTPHARM
Torrent Pharmaceuticals Limited
1.75 L cr77.9x9.6x17.0%15.2%0.7612.1%+50.8%0.82%
LAURUSLABS
Laurus Labs Limited
1.25 L cr93.6x20.7x17.7%17.9%0.4017.0%+33.4%0.09%
ZYDUSLIFE
Zydus Lifesciences Limited
1.20 L cr28.9x4.3x18.3%19.9%0.4414.1%+29.2%0.08%
DRREDDY
Dr. Reddy's Laboratories Limited
1.17 L cr41.6x3.0x11.5%13.9%0.158.3%-1.5%0.57%
CIPLA
Cipla Limited
1.14 L cr39.5x3.2x11.7%16.0%0.0110.1%-2.4%0.92%
MANKIND
Mankind Pharma Limited
1.08 L cr48.3x6.2x12.4%12.9%0.3014.7%+17.3%0.00%
AUROPHARMA
Aurobindo Pharma Limited
1.03 L cr26.1x2.6x9.9%12.8%0.2110.8%+23.9%0.39%
LUPIN
Lupin Limited
90,173 cr17.3x3.8x26.9%28.8%0.2317.0%+11.1%0.91%
GLENMARK
Glenmark Pharmaceuticals Limited
74,679 cr51.5x6.7x14.1%20.4%0.089.2%-31.3%0.09%
ALKEM
Alkem Laboratories Limited
62,443 cr30.2x4.2x17.6%20.6%0.1213.4%+13.8%1.01%
BIOCON
Biocon Limited
58,987 cr215.4x1.7x1.1%3.0%0.411.9%+2.2%0.14%
ABBOTINDIA
Abbott India Limited
54,122 cr32.7x----23.0%+11.0%2.58%
GLAND
Gland Pharma Limited
53,307 cr43.1x5.0x10.5%15.0%0.0217.5%+23.3%0.62%
IPCALAB
IPCA Laboratories Limited
47,039 cr33.5x5.4x13.2%16.6%0.0614.2%+13.8%0.32%
GLAXO
GlaxoSmithKline Pharmaceuticals Limited
44,693 cr39.5x23.8x48.9%66.5%0.0027.6%+20.8%2.16%
EMCURE
Emcure Pharmaceuticals Limited
44,294 cr40.5x8.3x19.6%24.8%0.2710.7%+24.3%0.15%
AJANTPHARM
Ajanta Pharma Limited
40,909 cr32.4x8.4x25.4%32.7%0.0220.3%+32.5%0.98%
SAILIFE
Sai Life Sciences Limited
37,978 cr100.5x14.1x15.1%20.9%0.1715.9%+22.5%0.00%
WOCKPHARMA
Wockhardt Limited
32,931 cr80.3x6.4x4.0%6.5%0.3910.8%+23.9%0.00%
ACUTAAS
Acutaas Chemicals Limited
32,677 cr74.4x17.6x23.5%31.7%0.0027.5%+42.7%0.06%
PPLPHARMA
Piramal Pharma Limited
31,813 cr-3.9x-4.0%0.8%0.69-2.1%+28.1%0.00%
NEULANDLAB
Neuland Laboratories Limited
27,527 cr60.8x13.6x21.4%27.5%0.1719.6%-12.6%0.16%
RUBICON
Rubicon Research Limited
27,450 cr84.1x19.4x19.1%23.4%0.2815.5%+39.9%0.09%
APLLTD
Alembic Pharmaceuticals Limited
20,528 cr24.3x3.5x12.4%11.7%0.259.9%+36.3%1.15%
GRANULES
Granules India Limited
19,762 cr27.6x3.0x13.5%15.7%0.0912.1%+20.3%0.22%
ERIS
Eris Lifesciences Limited
18,530 cr26.0x4.5x18.1%13.9%0.5821.6%+12.6%0.54%
ONESOURCE
Onesource Specialty Pharma Limited
18,189 cr-3.1x-1.3%0.4%0.25-0.1%+37.4%0.00%
SHILPAMED
Shilpa Medicare Limited
17,902 cr53.6x6.5x9.8%11.4%0.2418.1%+43.0%0.07%
ALIVUS
Alivus Life Sciences Limited
17,737 cr26.5x4.9x18.4%24.6%0.0024.9%+16.0%0.35%
PFIZER
Pfizer Limited
17,575 cr20.4x4.0x17.2%23.4%0.0032.4%+13.2%1.95%
COHANCE
Cohance Lifesciences Limited
17,462 cr507.1x4.5x5.1%8.0%0.06-0.3%-14.2%0.00%
NATCOPHARM
Natco Pharma Limited
16,098 cr17.7x1.6x16.9%17.1%0.1126.9%-29.0%0.70%
CAPLIPOINT
Caplin Point Laboratories Limited
15,851 cr23.0x4.1x19.9%24.7%0.0029.4%+17.9%0.38%
ASTRAZEN
AstraZeneca Pharma India Limited
15,109 cr85.0x17.2x22.8%31.2%0.006.8%+30.4%0.60%
JUBLPHARMA
Jubilant Pharmova Limited
14,870 cr56.2x2.1x6.0%8.7%0.542.9%+20.5%0.54%
CORONA
CORONA Remedies Limited
13,799 cr66.7x17.1x24.8%27.8%0.1213.3%+22.2%0.44%
MARKSANS
Marksans Pharma Limited
13,349 cr23.8x4.0x25.4%35.1%0.0116.7%+30.5%0.31%
BPLPHARMA
Bharat Parenterals Limited
1,682 cr------2.4%+110.9%0.04%

Swipe the table sideways for more columns. Tap a heading to sort. A dash means the figure is not filed or cannot be worked out for that company. A bigger cohort is cut to its 40 largest companies.

Monthly price changeThe share's price change in every calendar month, one row per year, so you can check for yourself whether a month has a pattern.

Month by month
YearJanFebMarAprMayJunJulAugSepOctNovDecYear
2026
·
·
·
·
·
·
·
·
+17.2
+13.2
+18.3
·
+57.0%
3m
Monthly movebelow -10%-10 to -5-5 to -2-2 to 00 to +2+2 to +5+5 to +10above +10%month in progress

Month-on-month change in closing price, adjusted for splits and bonuses but not for dividends, so a large dividend shows up here as a fall. Starts from 1995, when the exchange began trading equities, or from the stock's listing if later. This is a record of what happened, not a forecast.

Deals and filingsLarge trades reported to the exchange, plus the company's documents sorted by type.

No bulk or block deals on record for BPLPHARMA in the window we hold.

Read enough? Test BPLPHARMA. “Buy BPLPHARMA when RSI(14) drops below 30, sell at 10% profit or after 20 days.” Real prices, every charge counted.

Run it free